tbuckley/cabot-search huggingface dataset:
Infections and the risk of incident giant cell arteritis: a population-based, case-control study
Authors: Rennie L Rhee, Peter C Grayson, Peter A Merkel, Gunnar Tomasson
Journal: Annals of the Rheumatic Diseases (2016)

Alterations in the immune system and infections are suspected to increase susceptibility to giant cell arteritis (GCA). Recently herpes zoster has been directly implicated in the pathogenesis of GCA. We examined the association between prior infections, in particular herpes zoster, and incident GCA in a population-based cohort.A nested case-control study was performed using an electronic database from the UK. Cases with newly diagnosed GCA were identified using a validated algorithm and compared with age-matched, sex-matched and practice-matched controls. Conditional logistic regression was used to examine the relationship between any infection or herpes zoster infection on the development of GCA after adjusting for potential confounders; results were expressed as incidence rate ratios (IRRs).There were 4559 cases of GCA and 22 795 controls. Any prior infection and herpes zoster were associated with incident GCA (IRR 1.26 (95% CI 1.16 to 1.36), p<0.01; and 1.17 (95% CI 1.04 to 1.32), p<0.01, respectively). A greater number of infections was associated with a higher risk of developing GCA (IRR for 1, 2-4 and ≥5 infections was 1.28, 1.60 and 2.18, respectively).Antecedent infections and, to a lesser extent, herpes zoster infections are modestly associated with incident GCA. These data provide population-level support for the hypothesis that long-standing alterations of the immune system are associated with susceptibility to GCA and suggest that herpes zoster is unlikely to play a major causal role in the pathogenesis of GCA.
Hyaluronic Acid Enhances To Differentiate into Myelo-Megakaryocytic Lineages during Ex-Vivo Expansion of Human Cord Blood(HCB) Using TPO, SCF and FL.
Authors: Yeung-Chul Mun, Jee-Young Ahn, Kyung-Eun Lee, Eun-Sun Yoo, Sang min Lee, Yun-Kyung Bae, Seung-Eun Lee, Min Kyoung Kim, Myung Soo Hyun, Chu-Myong Seong
Journal: Blood (2005)
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Authors: Mark C. Genovese, Josef S. Smolen, Michael E. Weinblatt, Gerd R. Burmester, Sebastian Meerwein, Heidi S. Camp, Li Wang, Ahmed A. Othman, Nasser Khan, Aileen L. Pangan, Steven Jungerwirth
Journal: Arthritis & Rheumatology (2016)

Objective To evaluate the efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in patients with moderate‐to‐severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Methods Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate‐release ABT‐494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 weeks. The primary efficacy end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 12, as determined using the last observation carried forward method. Results At week 12, the proportion of ACR20 responses was higher with ABT‐494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, respectively) than with placebo (46%) (using nonresponder imputation) ( P &lt; 0.05 for the 6, 12, and 24 mg doses). There was a significant dose‐response relationship among all ABT‐494 doses ( P &lt; 0.001). The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT‐494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP). Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28‐CRP for all doses compared with placebo at week 2 (the first postbaseline visit). The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent. One serious infection (community‐acquired pneumonia) occurred with ABT‐494 at 12 mg. There were dose‐dependent increases in high‐density lipoprotein (HDL) and low‐density lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12. Mean hemoglobin levels remained stable at lower doses, but decreases were observed at higher doses. Conclusion This study evaluated a broad range of doses of ABT‐494 in RA patients with an inadequate response to MTX. ABT‐494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.
Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)
Authors: Nicholas Achille, Laura Michaelis, Scott E. Smith, Eliza Germano, Nancy J. Zeleznik-Le, Sucha Nand
Journal: Blood (2011)
P0922 : The combination of probiotics and prebiotics supplementation improves lipid metabolism, NAFLD and obesity in ob/ob mice
Authors: J.T. Stefano, M.M. Torres, I.V.A. Pereira, D. Jimenez, B. Muntanelli, F.M. Malta, B. Cogliati, J.R.R. Pinho, F.J. Carrilho, C.P. Oliveira
Journal: Journal of Hepatology (2015)
Phase I study of weekly intraperitoneal paclitaxel combined with S-1 and oxaliplatin for gastric cancer with peritoneal metastasis.
Authors: Hironori Ishigami, Shoichi Kaisaki, Hironori Yamaguchi, Hiroharu Yamashita, Shigenobu Emoto, Joji Kitayama
Journal: Journal of Clinical Oncology (2012)

146 Background: Intraperitoneal (IP) chemotherapy is a promising treatment option for gastric cancer with peritoneal metastasis. We previously verified the safety and efficacy of IP paclitaxel (PTX) combined with S-1 and intravenous PTX in phase I and phase II studies. S-1 plus oxaliplatin (SOX) demonstrated efficacy in a phase II study, and is regarded as a candidate for the next-generation standard regimen for gastric cancer. We designed a new regimen combining weekly IP PTX with SOX in order to maximize systemic effects as well as local effects in the peritoneal cavity. A dose-escalation study of IP PTX in combination with fixed doses of SOX was carried out to determine the maximum-tolerated dose (MTD) and recommended dose (RD). Methods: PTX was administered intraperitoneally on days 1 and 8 with an initial dose of 20 mg/m 2 (level 1), stepped up to 30 mg/m 2 (level 2) or 40 mg/m 2 (level 3) depending on observed toxicity. S-1 was administered orally at a dose of 80 mg/m 2 /day (b.i.d.) for 14 days followed by a 7-day rest. Oxaliplatin was administered intravenously at a dose of 100 mg/m 2 on day 1. This treatment was repeated every 3 weeks. Toxicity was graded according to CTCAE v4.0. Dose-limiting toxicities (DLTs) were defined as grade 4 leukopenia, grade 3 febrile neutropenia, grade 3 thrombocytopenia, and grade 3 non-hematological toxicity. The MTD was defined as the dose level at which 2 or more of 3 or 6 patients developed DLTs during two courses of treatment. The RD was defined as one dose level under the MTD. Results: A total of 12 gastric cancer patients with peritoneal metastasis were enrolled. No DLTs were observed at all dose levels. Neutropenia in one patient at dose level 3 was the only grade 3 toxicity observed. Grade 2/3 leukopenia, neutropenia and thrombocytopenia were observed only in 2 patients at dose level 3. Regarding grade 2 non-hematological toxicities, anorexia, fatigue and nausea were observed in 6, 4 and 2 patients, respectively, independent of dose levels. Consequently, the MTD was not reached, and the RD of IP PTX was determined to be 40 mg/m 2 (level 3). Conclusions: Combination chemotherapy of IP PTX with SOX was shown to be a safe regimen that should be further explored in clinical trials.
Magnetic Resonance Imaging Exposure During Pregnancy
Authors: Sean P. Symons, Chris Heyn, Pejman Jabehdar Maralani
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of bevacizumab on sinusoidal injury in patients receiving oxaliplatin-based chemotherapy and liver damage after massive hepatectomy in rats.
Authors: Mitsuo Shimada, Toru Utsunomiya, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Tomohiko Miyatani, Hirohiko Sato, Nobuhiro Kurita
Journal: Journal of Clinical Oncology (2012)

276 Background: The aim of this study was to clarify impact of bevacizumab (Bev) on both hepatic sinusoidal injury after oxaliplatin (L-OHP)-based chemotherapy for metastatic colorectal cancer, and on liver regeneration after massive hepatectomy (Hx). Methods: &lt;Study 1: Clinical&gt; Fourteen patients who underwent Hx after receiving L-OHP-based chemotherapy for liver metastases from colorectal cancer were divided into two groups (Bev group (n=8) and No-Bev group (n=7)). Histology of non-cancerous liver tissue, blood chemistry such as hyaluronic acid (HA), spleen size, and postoperative complications were compared between the two groups. &lt;Study 2: Experimental&gt; Male Wister rats that underwent 90%-Hx were divided into two groups (Control group (n=7) and Bev group (n=7), in which Bev was injected intraperitoneally (5mg/kg) 7days before Hx). The following parameters were compared; blood chemistry, liver weight to body weight (Lw/Bw) ratio, and cytokines in liver tissues by RT-PCR, and survival rate. Results: &lt;Study 1&gt; Incidence of sinusoidal dilatation in Bev group was lower than that in No-Bev group (25% vs. 67%). Serum HA before Hx in Bev group (28 ng/ml).was lower than that in No-Bev group (155ng/ml). Spleen size in Bev group (174 ml) tended to be smaller than that in No-Bev group (252 ml). No significant postoperative complication was observed in Bev group, while 4 out of 7 patients had complications in No-Bev group. &lt;Study 2&gt; Liver damage such as ALT in Bev group (1471 IU/L) was smaller than that in Control group (2287 IU/L). Regeneration rate (Lw/Bw ratio) in Bev group was greater than that in Control group (0.80 vs. 0.67). Expression levels of IL-1β, MMP2 and MMP9 in Bev group tended to be lower than those in Control group. Survival rate at 72 hours after Hx in Bev group (83%) tended to be better than that in Control group (50%). Conclusions: Bev could reduce sinusoidal injury in patients with L-OHP-based chemotherapy, furthermore, Bev reduced liver injury and promoted liver regeneration after massive hepatectomy in rats. Those data strongly suggest Bev has beneficial effects for patients receiving L-OHP-based chemotherapy who undergo massive Hx.
Use of cytokeratin 18 and EAU score to predict tumor recurrence in patients with non-muscle-invasive bladder cancer following single postoperative immediate intravesical chemotherapy instillation.
Authors: M. Horinaga, S. Murata, M. Matsushima, Y. Nakahira, H. Yanaihara, M. Ueno, H. Asakura
Journal: Journal of Clinical Oncology (2011)

269 Background: We examined the prognostic factors for recurrence after TURBT using molecular markers as well as the scoring system of the EAU. Methods: Eighty-eight patients with primary or recurrent bladder tumors who underwent TURBT followed by the single postoperative immediate instillation of pirarubicin and no further instillations were enrolled between 2003 and 2006; the median follow-up period was 46 months. The time to first recurrence was the primary end point of this study. Patients were divided into EAU recurrence risk groups as follows: low-risk group (total score, 0), intermediate-risk group (total score, 1-9) and high-risk group (total score, 9-17). The intermediate-risk group patients were subdivided into a total score of 1-4 and a total score of 5-9. Immunostaining using Ki-67, pHH3, CK18 and Survivin were performed on the TURBT specimens. Results: According to the risk stratification, 5, 82, and 1 were assigned to the low-, intermediate-, and high-risk recurrence groups, respectively. During the follow-up, recurrences were observed in 0% of the low-risk group, 45% (37 out of 82) in the intermediate-risk group and 100% in the high-risk group. We evaluated various predictors of a recurrence-free outcome among the 82 intermediate-risk patients. In univariate analyses, EAU score (1-4, 32.1% vs 5-9, 62.1%; p = 0.0011), high CK18 expression (negative, 31.4% vs positive 88.8%; p &lt; 0.0001), high Ki-67 index (&lt; 5%, 35.4% vs &gt; 5%, 52.5%; p = 0.017) and high Survivin nuclear staining (&lt; 5%, 35.9% vs &gt; 5%, 62.5%; p = 0.004) were associated with recurrence. In a multivariate analysis, EAU score (HR 2.95, p = 0.003) and a high CK18 immunostaining (HR 6.70, p &lt; 0.0001) were independent predictors of disease recurrence. Conclusions: A single immediate chemotherapy instillation is, by itself, insufficient for the treatment of patients in the intermediate- or high-risk recurrence groups defined by the EAU guidelines. Strong immunohistochemical expression of CK18 and the EAU scoring system appeared to be independent predictors of clinical outcome among patients with urothelial carcinoma of the bladder. No significant financial relationships to disclose.
Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.
Authors: Paul Brennan, Suhair Alghazal, Naomi Price Lloyd, Janet E. Williams, Jeff D. Griffiths, Clare Rowntree, Guy Pratt, Chris Fegan, Chris Pepper
Journal: Blood (2006)
Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)
Authors: Edward A Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Kristin Knust, Asad Bashey, Steven M. Devine, Yvonne A Efebera, Siddhartha Ganguly, Cristina Gasparetto, Nancy Geller, Sergio A. Giralt, Parameswaran Hari, Mary M. Horowitz, John Koreth, Heather Landau, Philip L. McCarthy, Brian McClune, Courtney Nelson, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Ravi Vij, Dan T. Vogl, George Somlo, Amrita Krishnan
Journal: Blood (2016)
Human CD21low CD86pos B Cells Are Potent Antigen Presenting Cells, Which Are Expanded in Inflammatory Conditions
Authors: Alexander Shimabukuro-Vornhagen, María Alejandra García-Márquez, Rieke N. Fischer, Juliane Iltgen-Breburda, Anne Fiedler, Kerstin Wennhold, Gunter Rappl, Hinrich Abken, Pia Hartmann, Clara Lehmann, Thomas Koslowsky, Marco Herling, Dirk Beutner, Dominik Wolf, Gerd Fätkenheuer, Andrea Rubbert-Roth, Michael Hallek, Sebastian Theurich, Michael von Bergwelt-Baildon
Journal: Blood (2015)
Influence of PET/CT on therapeutic management after resection of high-risk or very high-risk GIST.
Authors: J. Bertz-Lepel, J. Rahm, D. Pink, D. Schoeler, P. Reichardt
Journal: Journal of Clinical Oncology (2011)

e20516 Background: After resection of GIST, accurate staging is crucial in order to optimize disease management. Patients (pts) with big tumor size, high mitotic activity and unfavourable localization of primary tumor have a high risk of recurrence. This study was performed to analyse the influence of PET/CT on further therapy management after resection of GIST. Methods: 34 pts underwent PET/CT four to eight weeks after R0 resection of a primary GIST and all known metastases. 29 of them had preoperative imaging by CT-scan and/or ultrasound. Minimum follow-up with regular CT imaging is 5 years. Results: According to the Miettinen risk classification system, 28 pts were classified as high risk GIST. 6/34 pts had metastatic GIST with complete resection of all known metastases. In 3/28 primarily non-metastatic pts and 2/6 primarily metastatic pts, metastases were detected by PET/CT. In one non-metastatic patient, an early stage small cell lung cancer was diagnosed. Wrong positive results occurred in 5/34 pts with one being identified as “sarcoid like lesion” and one as “inflamed urinary calculi”. One patient with positive PET/CT was diagnosed with postoperative abscess and underwent re-laparotomy. Two wrong positive results without clinical relevance occurred in pts who underwent PET/CT less than 6 weeks after operation. Overall, a higher rate of unspecific findings was reported if PET/CT was performed less than 6 weeks after surgery. In 3 pts, suspicious lesions described preoperatively could be identified as non-malignant by PET/CT with no metastases detected during follow-up. There were two wrong negative results with lesions interpreted as unspecific findings by PET/CT and subsequently identified as metastases. Conclusions: If PET/CT is performed not earlier than 6 to 8 weeks after surgery, it can improve the diagnostic accuracy and influence treatment decision.
Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.
Authors: Maria T. Krauth, Hermine Agis, Karl J. Aichberger, Ingrid Simonitsch, Leonhard Muellauer, Matthias Mayerhofer, Hans P. Horny, Peter Valent
Journal: Blood (2004)
High response rates with bevacizumab, docetaxel, and carboplatin in patients with HER2-negative advanced breast cancer: An experience of 22 case reports.
Authors: G. Tellez-Trevilla, P. Cabrera-Galeana, E. Gomez-Plata, J. L. Barrera-Franco, H. Astudillo
Journal: Journal of Clinical Oncology (2011)

e11538 Background: Monoclonal antibodies, such as bevacizumab, stop tumor growth and block the ability of tumor cells to grow and spread. Others drugs find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with docetaxel and carboplatin may kill more tumor cells. The aim of this study was to determine the clinical response rate in women with metastatic breast cancer and Her2 negative treated with bevacizumab, docetaxel, and carboplatin. Methods: Twenty two patients Her2 negative with diagnostic of metastatic breast cancer were included and received bevacizumab (15mg/kg), docetaxel (75mg/m2), and carboplatin (AUC 5) on day 1 and were repeated every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity. Results: Overall clinical response rate was 80% (18/22) and it was assessed by RECIST criteria using CT and PET-CT. Surprisingly, the complete clinical response rate was about 40% (9/22) in all patients. Progression disease-free survival was between 7-14 months. At this moment 22% (5/22) of patients have been recurred. Safety and tolerability were acceptable; in only 9% (2/22) patients were observed an acute anaphylactic response (dysnea, hyperthermia, anxiety and puritus) without serious adverse events. Conclusions: This study strongly suggests that the inclusion of bevacizumab in combination with docetaxel and carboplatin do not increase the toxicity profile previously reported for these chemotherapy drugs and increase the clinical response rate. At this moment there is not previous report about the use of these agents combination in Her2 negative advanced breast cancer patients and it could be a very hopeful new treatment for this kind of patients. A new prospective study with a large patient number we consider for a near future.
Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Authors: Koji Sasaki, Elias J. Jabbour, Susan M. O'Brien, Farhad Ravandi, Deborah A Thomas, Tapan M. Kadia, Guillermo Garcia-Manero, Jan A. Burger, Naveen Pemmaraju, Yesid Alvarado, Naval G. Daver, Nitin Jain, Marina Konopleva, Richard E. Champlin, Issa F. Khouri, Partow Kebriaei, David Marin, Courtney D DiNardo, Zeev Estrov, Koichi Takahashi, Nicholas J. Short, Maria R. Khouri, Jovitta Jacob, Rebecca Garris, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2016)
Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST).
Authors: L. D'Ambrosio, A. Ponzetti, P. Lista, S. Bombaci, E. Palesandro, D. Galizia, S. Aliberti, P. Allione, A. Manca, S. Gallo, G. Grignani, M. Aglietta
Journal: Journal of Clinical Oncology (2011)

e20514
Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients
Authors: Evangelos Terpos, Vassilis Koutoulidis, Sofia Fontara, Flora Zagouri, Dimitrios Christoulas, Dimitris Matsaridis, Andreas Koureas, Efstathios Kastritis, Meletios A. Dimopoulos, Lia A. Moulopoulos
Journal: Blood (2015)
LRRK2 at the interface of autophagosomes, endosomes and lysosomes
Authors: Dorien A. Roosen, Mark R. Cookson
Journal: Molecular Neurodegeneration (2016)

Over the past 20 years, substantial progress has been made in identifying the underlying genetics of Parkinson’s disease (PD). Of the known genes, LRRK2 is a major genetic contributor to PD. However, the exact function of LRRK2 remains to be elucidated. In this review, we discuss how familial forms of PD have led us to hypothesize that alterations in endomembrane trafficking play a role in the pathobiology of PD. We will discuss the major observations that have been made to elucidate the role of LRRK2 in particular, including LRRK2 animal models and high-throughput proteomics approaches. Taken together, these studies strongly support a role of LRRK2 in vesicular dynamics. We also propose that targeting these pathways may not only be beneficial for developing therapeutics for LRRK2-driven PD, but also for other familial and sporadic cases.
Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.
Authors: Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Miloslav Beran, Michael Rytting, Charles A. Koller, Srdan Verstovsek, Gautam Borthakur, Michael Andreeff, Steve Kornblau, Khanh Vu, Rita Jarmon, Hagop M. Kantarjian
Journal: Blood (2005)